Antihypertensive effect and tolerability of perindopril in Indian hypertensive and type 2 diabetic patients. 1-year randomised, double-blind, parallel study vs atenolol

Clinical Drug Investigation

Volumn 16, Issue 3, 1998, Pages 229-240

  Seedat, Yackoob K ^a   Randeree, Ismail G H ^b  

^a UNIVERSITY OF NATAL   (South Africa)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROCHLOROTHIAZIDE; NIFEDIPINE; PERINDOPRIL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; INDIAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SITTING; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; VERTIGO;

EID: 0031668839     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816030-00007     Document Type: Article

References (40)

1. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319 (23): 1517-25
2. 1989 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertension 1989; 7(8): 689-93
3. Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther 1988; 44 (4): 418-25
4. Bussien JP, Fasanella d'Amore T, Perret L, et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clin Pharmacol Ther 1986; 39 (5): 554-8
5. Lees KR, Reid JL. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. Br J Clin Pharmacol 1987; 23 (2): 159-64
6. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157 (21): 2413-46
7. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 1997; 20 Suppl. 1: S1-70
8. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23(2): 145-58
9. Curb JD, Pressel SL, Cutler JA, et al. for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276 (23): 1886-92
10. Shorr RI, Ray WA, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278 (1): 40-3
11. Lewis EJ, Hunsicker LG, Bain RP, et al. for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329 (20): 1456-62
12. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996; 156 (3): 286-9
13. Kasiske BL, Kalil, RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118 (2): 129-38
14. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50 (5): 1641-50
15. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45 (2): 216-22
16. Luccioni R, Frances Y, Gass R, et al. Evaluation of the dose-effect relationship of a new ace inhibitor (perindopril) by an automatic blood pressure recorder. Eur Heart J 1988; 9 (10): 1131-6
17. Asmar RG, Pannier BM, Santoni JP, et al. Angiotensin converting enzyme inhibition decreases systolic blood pressure more than diastolic pressure as shown by ambulatory blood pressure monitoring. J Hypertens 1988; 6(3): S79-81
18. West JN, Smith SA, Stallard TJ, et al. Effects of perindopril on ambulatory intra-arterial blood pressure, cardiovascular reflexes and forearm blood flow in essential hypertension. J Hypertens 1989; 7 (2): 97-104
19. Morgan T, Anderson A, Wilson D, et al. The effect of perindopril on blood pressure in humans on different sodium intakes. J Cardiovasc Pharmacol 1987; 10 Suppl. 7: S116-8
20. Seedat YK. Race, environment and blood pressure: the South African experience. J Hypertens 1983; 1 (1): 7-12
21. Seedat YK, Mayet FG, Khan S, et al. Risk factors for coronary heart disease in the Indians of Durban. S Afr Med J 1990; 78 (8): 447-54
22. Seedat YK, Mayet FGH, Joubert G. Insulin resistance and hypertension: a study of coronary heart disease in the Durban Indians. Coron Artery Dis 1991; 2 (10): 1089-91
23. Helgeland A, Strommen R, Hageland CH, et al. Enalapril, atenolol and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. Lancet 1986; 1 (8486): 872-5
24. Bolzano K, Arriaga J, Bernal R, et al. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: S43-7
25. Beevers DG, Blackwood RA, Garnham S, et al. Comparison of lisinopril versus atenolol for mild to moderate essential hypertension. Am J Cardiol 1991; 67 (1): 59-62
26. Degaute JP, Leeman M, Desche P. Long-term acceptability of perindopril: European multicenter trial on 856 patients. Am J Med 1992; 92 (4B): 84S-90S
27. Zanchetti A, Desche P. Perindopril: first-line treatment for hypertension. Clin Exp Hypertens A 1989; 11 Suppl. 2: 555-73
28. Morgan T, Louis W, MacDonald GJ, et al. Antihypertensive efficacy and safety of perindopril in mild to moderate essential hypertension: results of a double blind multicentre study versus atenolol. Am J Med 1992; 92 (4B): 73S-78S
29. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982; 14: 97S-101S
30. Seedat YK. Varying responses to hypotensive agents in different racial groups: black versus while differences. J Hypertens 1989; 7 (2): 515-8
31. Weinberger MH. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1982; 14 Suppl. 2: 127S-131S
32. Pool JL, Gennari J, Goldstein R, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: S36-42
33. Brown CL, Backhouse CI, Grippal JC, et al. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990; 39 (4): 327-32
34. Fuh MM, Sheu WH, Shen DC, et al. Metabolic effects of diuretic and beta-blocker treatment of hypertension in patients with non-insulin-dependent diabetes mellitus. Am J Hypertens 1990; 3 (5 Pt 1): 387-90
35. Elving LD, de Nobel E, van Lier HJ, et al. A comparison of the hypotensive effects of captopril and atenolol in the treatment of hypertension in diabetic patients. J Clin Pharmacol 1989; 29 (4): 316-20
36. Gall MA, Rossing P, Skott P, et al. Placebo controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. Am J Hypertens 1992; 5 (5 Pt 2): 257-65
37. Rett K, Wicklmayr M, Dietze GJ, et al. Effects of captopril (C) and metoprolol (M) on glycemic control, lipid profile and coronary risk in hypertensive patients with non-insulin-dependent diabetes (NIDDM). Diabetes 1990; 39 Suppl. 1: 172
38. Tuck ML. Diabetes and hypertension. Postgrad Med J 1988; 64 Suppl. 3: 76-83
39. Woo KS, Norris RM, Nicholls G. Racial differences in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 1995; 75 (14): 967-8
40. Yeo WW, Maclean D, Richardson PJ, et al. Cough and enalapnl assessment by spontaneous reporting and visual analogue scale under double-blind conditions. Br J Clin Pharmacol 1991; 31 (3): 356-9